Page last updated: 2024-08-21

quinazolines and gw 3965

quinazolines has been researched along with gw 3965 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albers, M; Blume, B; Deuschle, U; Kober, I; Koegl, M; Kremoser, C; Schlueter, T; Wright, MB	1
Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wang, Z; Wu, J; Wu, Y; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L	1

Other Studies

2 other study(ies) available for quinazolines and gw 3965

Article	Year
A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. The Journal of biological chemistry, 2006, Feb-24, Volume: 281, Issue:8 Topics: Benzoates; Benzylamines; Binding, Competitive; Cell Line; Cell-Free System; DNA Primers; DNA-Binding Proteins; Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Gene Expression Regulation; Humans; Hydroxycholesterols; Ligands; Liver X Receptors; Models, Chemical; Molecular Conformation; Orphan Nuclear Receptors; Peptides; Protein Binding; Quinazolines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Two-Hybrid System Techniques	2006
Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro. Oncotarget, 2017, Feb-28, Volume: 8, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Benzoates; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver X Receptors; Lung Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2017

Article

Year

A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors.

The Journal of biological chemistry, 2006, Feb-24, Volume: 281, Issue:8

Topics: Benzoates; Benzylamines; Binding, Competitive; Cell Line; Cell-Free System; DNA Primers; DNA-Binding Proteins; Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Gene Expression Regulation; Humans; Hydroxycholesterols; Ligands; Liver X Receptors; Models, Chemical; Molecular Conformation; Orphan Nuclear Receptors; Peptides; Protein Binding; Quinazolines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Two-Hybrid System Techniques

2006

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.

Oncotarget, 2017, Feb-28, Volume: 8, Issue:9

Topics: Antineoplastic Agents; Apoptosis; Benzoates; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver X Receptors; Lung Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2017